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Abstract: Six homologous gold(III) dinuclear oxo-bridged complexes, of the type [(bipynR)Au(µ-O)2Au(bipynR)][PF6]2, 
bearing variously substituted 2,2’-bipyridine ligands (bipynR
 
= 2,2’-bipyridine, 4,4’-di-tert-butyl-, 6-methyl-, 6-neopentyl-, 
6-o-xylyl- and 6,6’-dimethyl-2,2’-bipyridine), here called Auoxos, were prepared, characterised and recently tested as  
potential anticancer agents. Crystal structures were obtained for five members of the series that allowed us to perform  
detailed comparative analyses. Interestingly, the various Auoxos showed an acceptable stability profile in buffer solution 
and turned out to manifest outstanding antitumor properties in vitro. In particular, one member of this family, Auoxo6 
(bipynR = 6,6’-dimethyl-2,2’-bipyridine), produced more selective and far greater antiproliferative effects than all other 
tested Auoxos, qualifying itself as the best “drug candidate”. In turn, COMPARE analysis of the cytotoxicity profiles of 
five Auoxos, toward an established panel of thirty-six human tumor cell lines, revealed important mechanistic differences; 
a number of likely biomolecular targets could thus be proposed such as HDAC and PKC. Biophysical studies revealed 
markedly different modes of interaction with calf thymus DNA for two representative Auoxo compounds. In addition, a 
peculiar reactivity with model proteins was documented on the ground of spectrophotometric and ESI MS data, most 
likely as the result of redox processes. In view of the several experimental evidences gathered so far, it can be stated that 
Auoxos constitute a novel family of promising cytotoxic gold compounds with an innovative mechanism of action that 
merit a more extensive pharmacological evaluation. 
Keywords: Anticancer drugs, X-ray structures, gold complexes, cytotoxic activity, mechanisms of action, gold protein com-
plexes, gold DNA complexes.  
1. INTRODUCTION 
 Gold compounds are increasingly attracting researchers’ 
attention as a source of novel cytotoxic substances, of poten-
tial use in cancer treatment. In particular, several gold(III) 
compounds, with profoundly different molecular structures, 
have been designed, synthesized and tested as antiprolifera-
tive agents during the last decade [1-5]. Very relevant cyto-
toxic properties were disclosed for many gold(III) com-
pounds and initial structure-function relationships outlined 
[6-8]. From those studies, it emerged rather clearly that 
gold(III) compounds must be considered, in general, as  
prodrugs and that their biological activities, subsequent to 
chemical activation, primarily arise from gold coordination 
to specific sites of target biomolecules or, alternatively, from 
gold-centred redox reactions and consequent oxidative dam-
age. However, some notable exceptions to this rule were 
reported as well (see, for instance, the case of stable gold(III) 
porphyrins) [8]. It is also evident that the relevant cytotoxic  
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effects produced by gold(III) compounds are afforded, in 
most cases, through biochemical mechanisms that are sub-
stantially different from those typical of platinum drugs and 
essentially “DNA independent” [1]. The occurrence of a 
different mechanism of action seems to be a very attractive 
feature for this novel class of cytotoxics as it might lead to 
the development of novel drugs capable of overcoming the 
severe problem of cisplatin (CDDP) resistance. 
 As the molecular framework of the metal apparently 
plays a crucial role in modulating the overall chemical and 
biological reactivity of the metal centre itself, appropriate 
and increasingly sophisticated chemical architectures need to 
be designed and built up for the improvement of the pharma-
cological properties of these metallodrugs [9, 10]. In recent 
years, a rather common strategy in the field of “Anticancer 
metal based drugs” has been the design of dinuclear or 
polynuclear derivatives [11]. Such a “multinuclear” strategy 
produced promising results in the case of anticancer  
platinum drugs [12] and was recently extended to non-
platinum compounds such as ruthenium compounds [13]. 
We have applied this synthetic approach to gold(III)  
compounds and prepared a series of dinuclear complexes, 
named Auoxos, characterised by the presence of a Au2O2  
“diamond” core and of variously substituted 2,2'-bipyridyl 
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ligands (bipynR) [14]. We describe here the main features of 
the synthesis, the structural chemistry, the reactivity and the 
biological properties of this novel family of gold-based 
agents, as they emerge from our recent investigations. The 
perspectives for their future use as anticancer agents will be 
also discussed. 
2. DESIGN AND SYNTHESIS OF AUOXO COM-
POUNDS 
 A few years ago we evaluated the biological properties of 
the mononuclear square planar gold(III) compound [Au 
(bipy)(OH)2][PF6], AuOH1, featuring a chelating 2,2’-
bipyridine and two hydroxo groups as ligands. AuOH1 was 
found to manifest appreciable cytotoxic properties against a 
few standard human tumor cell lines; however, we noticed 
that its stability in aqueous solutions was rather poor and not 
very adequate for pharmaceutical purposes. A substantial 
improvement in terms of stability in solution (mainly with 
respect to ligand substitution reactions) could be obtained as 
the result of the condensation reaction of two AuOH1 units 
to give the dinuclear oxo-bridged derivative [(bipy)Au(µ-
O)2Au(bipy)][PF6]2, Auoxo1. Interestingly, this reaction may 
be reverted by refluxing Auoxo1 in water over several hours. 
In Fig. (1) AuOH1 and its dinuclear derivative Auoxo1 are 
schematically represented. 
 Unfortunately, “duplication” of the starting compound, 
while producing a higher stability in solution, did not result 
into significantly improved performances in terms of cyto-
toxicity. 
 Nonetheless, upon introduction of various substituents on 
the 2,2’-bipyridine backbone, we were able to modulate the 
pharmacological properties of the dinuclear parent com-
pound. As a result of this strategy, five further oxo bridged 
complexes of the type [(bipynR)Au(µ-O)2Au(bipynR)][PF6]2 
(bipynR = 4,4’-di-tert-butyl-2,2’-bipyridine, Auoxo2; 6-
methyl-2,2’-bipyridine, Auoxo3; 6neopentyl-2,2’-bipyridine, 
Auoxo4; 6-o-xylyl-2,2’-bipyridine, Auoxo5; 6,6’-dimethyl-
2,2’bipyridine, Auoxo6) (Fig. 2) were prepared and fully 
characterized; afterward, some aspects of their biological 
properties were investigated in depth [14]. 
 Auoxo2 was prepared according to the same procedure 
used for Auoxo1, i.e. by the condensation reaction of the 
dihydroxo complex [Au(bipy2tBu)(OH)2][PF6], AuOH2. At 
variance, Auoxo3-Auoxo6 were obtained by reaction of the 
neutral adducts [Au(bipynR)Cl3] with NaOAc and excess 
K[PF6] in aqueous solution. Auoxo3 was obtained as a ca. 
1:1 mixture of the cis and trans isomers, while, in the case of 
Auoxo4 and Auoxo5, only trans isomers were formed. In this 






Fig. (1). Schematic drawing of the synthesis of Auoxo1. 
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3. STRUCTURAL CHARACTERISATION 
 The solid state X-ray crystal structures of five com-
pounds of the series (namely Auoxo1, cis-Auoxo3, Auoxo4, 
Auoxo5, and Auoxo6) are now available [15]. Despite nu-
merous attempts, crystals of Auoxo2, [(bipy2tBu)Au(µ-
O)2Au(bipy2tBu)][PF6]2, could not be obtained. The crystal 
structures for four Auoxo compounds, recently solved in our 
laboratory, are depicted in Fig. (3). 
 The metal complex, two hexafluorophosphate (PF6-) ani-
ons, and one acetonitrile molecule are present in the asym-
metric unit of cis-Auoxo3. In those of Auoxo1 and Auoxo5 
half of the metallic cation, one PF6- anion and one acetoni-
trile solvent molecule are found. In the asymmetric unit of 
Auoxo6, one fourth of the metal complex and half of a hex-
afluorophosphate anion have been identified. Upon consider-
ing the structure of Auoxo4, reported in a previous study 
[16], all these binuclear gold(III) compounds have in com-
mon the approximately planar “diamond core” system Au2O2 
and the bipyridyl rings of the ligands. With this in mind, and 
taking the Auoxo1 complex as the reference compound for 
the whole series, structural parameters of Auoxo1, cis-
Auoxo3, Auoxo4, Auoxo5, and Auoxo6 were analysed (re-
ported in Table 1) in such a way to highlight the effects on 
them of the different substituents. 
 The “diamond core” system”, that is planar because of 
the inversion centre in Auoxo1, Auoxo5, and Auoxo6 [15] 
and because the deviation is not significant for Auoxo3, 
shows an interesting trend relating the Au···Au and O···O 
distances across the series of examined compounds. As re-
ported in Table 1, while the distance between the two gold 
atoms increases along the series (in the order Auoxo1 < 
Auoxo5 < cis-Auoxo3 < Auoxo4 < Auoxo6), the correspond-
ing O···O distance decreases. This grouping is coplanar with 
the five-membered ring formed by Au(1)−N(1)−C 
(5)−C(6)[C(5′)]−N(2)[N(1′)] in each complex [and by the 
Au(2)−N(3)−C(16) −C(17)−N(4) ring in cis-Auoxo3]; the 
maximum deviation is 2.5(2)° in the case of cis-Auoxo3. In 
Auoxo6 the two planes form an angle of 6.44(9)°. Moreover, 
in Auoxo5, the xylyl ring and the bipyridine moiety are al-
most perpendicular (76.1(2)°). When considering each metal 
centre, the coordination is basically planar, the largest devia-
tion from the best plane containing the coordination ion be-
ing found for Au(1) in Auoxo5 (0.14 Å out of the plane). 
 The distances between the two metal atoms vary from 
2.96 to 3.04 Å. These values are shorter than the sum of the 
van der Waals radii for two gold atoms (3.60 Å), even 
shorter than those found for other dinuclear complexes, e.g. 
Au2(XRn)2 (XRn = NR2, OR, SR, Cl, Br), [15, 17] implying 
the occurrence of a weak Au···Au interaction. Indeed, theo-
retical studies revealed that the strength of gold-gold interac-
tions largely depends on the gold oxidation state and that 
appreciable metal-metal interactions occur when both gold 
centres are in the oxidation state +3 [18]. 
 Upon analysing the influence of the alkyl or aryl sub-
stituents of the bipirydiyl rings, at position 6, on the coordi-
nation bond lengths, it may be pointed out that, in cis-
Auoxo3, trans-Auoxo5, and Auoxo6, they cause a significant 
increase in the Au−N distance adjacent to the substituent 
itself (e.g., to 2.07 Å in Auoxo6) in comparison to Auoxo1. 
The other Au−N distance in both cis-Auoxo3 and Auoxo5 
remains nearly unchanged; the same trend was found in 
Auoxo4. At variance with the Au-N distances, the Au−O 
bond lengths do not vary appreciably (1.97 Å), and this latter 
value is in agreement with the same distance found for 
mononuclear gold(III) alkoxo complexes supported by 2,2′-
bipyridines [15]. The only exception is the O(1)−Au(2) bond 
length in complex Auoxo3 which is significantly shorter. 
 The occurrence of substituents on the bipyridyl rings, in 
position 6, also affects the N−Au−O angle facing the sub-
stituent itself. In the reference compound Auoxo1, the angles 
N(1)−Au(1)−O(1) and N(2)−Au(1)−O(2) are 98.1(2)° and 
98.8(2)°, respectively. In Auoxo6 they both measure 
102.3(3)°; in cis-Auoxo3 and Auoxo5 the N(2)−Au(1)−O 
(2)[O(1′)] angles [and N(4)−Au(2)−O(2) in cis-Auoxo3] are 
larger than N(1)−Au(1)−O(1) and cis- Auoxo3 N(3)−Au 
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tance and the larger N−Au−O angle most likely arise from 
the steric hindrance of the substituent. In nice agreement 
with this interpretation, short intermolecular contacts are 
detected in cis-Auoxo3 and Auoxo6, connecting the methyl 
pendant arms via a weak hydrogen bond: in cis- Auoxo3, 
O(2) is 2.88 Å far apart from C(11) and 2.84 Å from C(22), 
while in Auoxo6, the C(6)···O(1) contact is 2.81 Å. 
 Due to the presence of many aromatic systems, in the 
lattice of cis-Auoxo3 and Auoxo5, different intramolecular 
and intermolecular interactions were identified. “Offset π-
stacked” interactions in cis-Auoxo3 involve the geometric 
centroids of the aromatic rings Ct2 and Ct3 (this latter be-
longs to a molecule related by −x + 1, −y, −z): the distance 
for the stacked aromatic rings is 4.03 Å. In Auoxo5 this kind 
of interaction involves the xylyl rings of the original mole-
cule and the molecule related by −x, −y, −z, the distance 
being 4.06 Å. Also CH/π interactions can be identified in the 
crystal lattice of the two above mentioned compounds. In 
cis-Auoxo3 the hydrogen atom H(11a) points directly to the 
centre (Ct1) of the aromatic ring of a molecule related by −x 
+ 1, −y, −z, the distance between them is 2.84 Å. In Auoxo5 
this kind of interaction is intramolecular and involves H(1) 
of the bipyridine ligand and the xylyl ring of the same mole-
cule: the distance H(1)···Ct1 is 2.99 Å. Moreover, in cis-
Auoxo3, an intermolecular interaction of 3.45 Å is found 
between Au(2) and O(2′) of a symmetry-related molecule 
(reported by −x + 1, −y, −z). 
4. THE SOLUTION BEHAVIOUR 
 The solution chemistry of the various Auoxo compounds 
was initially investigated through absorption UV−visible 
spectroscopy, upon consideration of their favourable optical 
properties. Notably, all six compounds are soluble and stable 
in DMSO, with retention of their characteristic binuclear 
structure. Accordingly, concentrated DMSO solutions of 
each binuclear gold(III) compound (1 × 10-2 M) were pre-
pared and then diluted into a standard 10 mM phosphate 
buffer, pH 7.4, to a final concentration of 5-10×10-5 M. The 
resulting samples were monitored spectrophotometrically 
over 24 h at 37 °C providing the spectral profiles that are 
shown in Fig. (4). Notably, all six compounds (dissolved in 
DMSO) exhibit intense absorptions in the 300−400 nm re-
Table 1. Selected Bond Distances (Å) and Angles (°) for Compounds Auoxo-1, -2, -3 and -4 
 Auoxo1 Auoxo3 Auoxo5 Auoxo6 
Au(1)-Au(2)[Au(1’)]a 2.9573(6) 3.0165(7) 2.9963(6) 3.044(1) 
Au(1)-O(1) 1.971(5) 1.972(7) 1.962(6) 1.955(5) 
Au(1)-O(2)[O(1’)]a 1.957(6)  1.976(7) 1.977(6)  
Au(1)-N(1) 2.015(4) 1.99(1) 2.023(7) 2.065(6) 
Au(1)-N(2) 2.000(4)  2.071(9) 2.081(7)  
Au(2)-O(1)  1.931(7)   
Au(2)-O(2)  1.975(7)   
Au(2)-N(3)  2.017(9)   
Au(2)-N(4)  2.028(9)   
Au(1)-O(1)-Au(2)[Au(1’)]a 97.7(2)  101.2(3) 99.0(2) 102.3(3) 
O(1)-Au(1)-N(1) 98.1(2)  95.4(3) 94.7(3) 100.8(3) 
O(1)-Au(1)-N(2) 178.9(2)  175.8(3) 174.3(2)  
O(1)-Au(1)-O(2)[O(1’)]a 82.3(2) 79.1(3) 81.0(2) 77.7(3) 
N(1)-Au(1)-N(2)[N(1”)]a 80.8(2)  80.4(4) 79.6(3) 80.4(4) 
N(1)-Au(1)-O2[O(1’)]a 179.2(2) 174.2(3) 175.6(2) 176.3(2) 
N(2)-Au(1)-O(2)[O(1’)]a 98.8(2)  105.1(3) 104.8(2)  
O(1)-Au(2)-N(3)  95.2(3)   
O(1)-Au(2)-N(4)  174.5(3)   
O(1)-Au(2)-O(2)  80.1(3)   
N(3)-Au(2)-N(4)  79.6(4)   
N(3)-Au(2)-O(2)  175.3(3)   
N(4)-Au(2)-O(2)  105.0(3)   
a Symmetry operations are as follows. Auoxo-1: ‘ = -x,-y+1,-z; -3: ‘ = -x,-y,-z+1; -4: ‘ = -x,-y,-z; “ = x,-y,z. 
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gion, straightforwardly assigned as LMCT bands. Upon dilu-
tion within the standard phosphate buffer, these transitions 
keep roughly unmodified in shape over 24 h observation (r), 
implying a substantial stability of the various dinuclear 
gold(III) chromophores. Nonetheless, some small spectral 
changes were noticed with time, probably related to the  
occurrence of initial hydrolysis processes and/or to the  
formation of some oligomeric species. In any case, the 
dinuclear species remain dominant in buffered aqueous  
solutions, for several hours. At variance with the other  
complexes, Auoxo5 manifested a progressive decrease in the 
intensity of its major LMCT band, at 310 nm. After 24 h, 
this band dropped to 60% of its initial intensity, without any 
significant shape modification. However, these relevant 
spectral changes could later be ascribed to the occurrence of 
precipitation phenomena and were reversed by modifying 
the composition of the medium (i.e. by increasing the 
amount of DMSO). 
 Extensive cleavage of the oxo bridges could only be 
achieved by applying far more drastic solution conditions. 
For instance, nearly complete conversion of Auoxo1 into its 
monomeric [Au(bipy)(OH)2]+ species (AuOH1) could be 
afforded after 2 h of incubation at 70°C [15]. 
 The stability of the various Auoxo compounds toward 
representative biological reductants was also assayed [14]. 
Ascorbic acid (AscA) was chosen as a typical reducing agent 
due to its widespread occurrence within biological fluids. 
Notably, addition of AscA, in a twofold molar excess, 
caused fast reduction of all six dinuclear gold(III) com-
pounds. The occurrence of gold(III) reduction was clearly 
witnessed by disappearance of the LMCT bands, characteris-
tic of the gold(III) bipyridyl chromophore; concomitantly, a 
broad absorption band showed up around 550 nm that is at-
tributed to the formation of colloidal gold, one of the typical 
products of gold(III) reduction. For comparison purposes, 






















Fig. (4). Hydrolysis profiles of Auoxos, in 10 mM phosphate, pH 7.4, at 37 °C; t = 0 (a) and t = 24 h (b). 
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also evaluated [14]. Similarly to ascorbic acid, GSH caused 
rapid disappearance of the characteristic LMCT bands, in 
agreement with gold(III) reduction. However, in contrast to 
the case of ascorbic acid, colloidal gold did not form. Most 
likely, the presence of an excess of glutathione favours the 
formation of soluble gold(I) thiolate species as a major prod-
uct of gold(III) reduction in the place of colloidal gold [19]. 
The overall results, obtained so far, disclose an appreciable 
sensitivity of Auoxos toward even mildly reducing condi-
tions, suggesting that these compounds, within the cellular 



























Fig. (5). Antiproliferative effects of Auoxos toward A2780/S (A) or 
A2780/R (B). 
5. THE ANTIPROLIFERATIVE PROPERTIES 
 The acceptable stability of the Auoxos, in aqueous solu-
tion, under physiological-like conditions, allowed us to per-
form an extensive testing of their antiproliferative properties 
in vitro. Initially, the cytotoxic properties of the Auoxo com-
pounds were assayed against the A2780 ovarian carcinoma 
human cell line, either sensitive (A2780/S) or resistant 
(A2780/R) to CDDP, according to the standard procedure 
described by Skehan et al. [20]. 
 Relevant cytotoxicity profiles and IC50 data are shown in 
Fig. (5) and Table 2 respectively. For comparison purposes 
the antiproliferative effects of the mononuclear precursor 
AuOH1 and of CDDP on the same cell lines are also re-
ported. 
 Notably, most Auoxos (Auoxo1−Auoxo5) were found to 
display remarkable and roughly comparable antiproliferative 
effects, with IC50 values typically falling in the 10−30 µM 
range; no relevant cross resistance with CDDP was high-
lighted. In contrast, Auoxo6 turned out to be far more active 
than all other complexes on both cell lines, with IC50 values 
of ca 2 µM for the sensitive line and ca 5 µM for the resis-
tant one. It follows that Auoxo6 is about 5 times more active 
than CDDP on the CDDP resistant line. 
 Afterward, the Auoxo compounds were analyzed at On-
cotest (Freiburg, Germany) according to specific screening 
strategies of new anticancer agents, as previously described 
(see http://www.oncotest.de) [21]. Initially, a standard 12-
cell-line panel was used, which allowed the various com-
pounds to be ranked according to their average cytotoxic 
potency. Then, the best performers were challenged on  
a wider 36-cell-line panel. This latter experiment, carried  
out on four Auoxo compounds (the best performers in the 
biological tests, i.e. Auoxo1, Auoxo4, Auoxo5 and Auoxo6), 
allowed us to assess, with a high reliability, the selectivity of 
the observed antitumor effects. The representative pattern of 
antiproliferative properties measured for Auoxo6 is shown in 
Fig. (6). Important differences were evident in their respec-
tive cytotoxic potencies and tumor selectivities as summa-
rised in Table 3. Again, Auoxo6 turned out to be the most 
active compound and to display appreciable tumor selectiv-
ity. These properties make Auoxo6 -by far- the most promis-
ing member of the series. 
 Finally, the results of the 36-cell-line experiments were 
analysed through the COMPARE algorithm [22, 23], to gain 
specific mechanistic information on each complex. Activity 
patterns of the assayed compounds were correlated to the 
patterns of the approximately 100 reference compounds with 
a known mechanism of action, tested in the Oncotest 36-cell-
line panel. Similarity in the cytotoxicity pattern is often  
Table 2. IC50 Values of Auoxos Toward A2780 Cells in Comparison to AuOH1 and Cisplatin (CDDP) 
IC50 (µM) 
Cell Lines CDDP AuOH1 Auoxo1 Auoxo2 Auoxo3 Auoxo4 Auoxo5 Auoxo6 
A2780/S 2.1±0.2 8.4±0.1 22.8±1.5 12.1±1.5 25.4±2.5 12.7±1.1 11.0±1.5 1.79±0.17 
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associated to similarity in the mechanism of action, in the 
resistance profile, and possibly in molecular structure [24]. 
 Overall, this kind of approach is aimed at establishing 
initial structure-function relationships, of potential interest 
for further drug design and development. COMPARE analy-
sis applied to the above Auoxo compounds provided quite 
interesting results (Table 3). In general, these results were 
less homogeneous than it could be expected on the basis of 
the strict structural similarity existing among the various 
Auoxos.  
 Auoxo6 revealed striking similarities to various histone 
deacetylase (HDAC) inhibitors, i.e. ρ=0.72 for both the ben-
zamide acetyldinaline and the cyclic peptide apicidin and 
ρ=0.61 for suberic bishydroxamate on the IC70 level [25]. 
Auoxo1 showed a nearly identical IC70 profile to AuOH1. A 
Spearman rank correlation [26] of the IC70 profiles of the 
latter two compounds revealed ρ=0.91, indicating a strong 
similarity in their respective biological behaviour. This find-
ing might be reasonably explained by assuming that Auoxo1, 
in the cellular milieu, may break down and convert into its 
monomeric form AuOH1. Pair wise, their potencies on the 
level of the mean IC50 and IC70 values were similar. COM-
PARE analysis indicated inhibition of protein kinase C 
(PKC) as the likely mechanism for their biological action. In 
fact, for both compounds, the PKC inhibitor UCN-01 (7-
hydroxystaurosporine) reached the top scoring (ρ=0.68 for 
AuOH1 and ρ=0.65 for Auoxo1 on the IC70 level). Auoxo4 
(mean IC70=22 µg/ml) exhibited a relatively weak potency, 
























Fig. (6). Anticancer profile of Auoxo6 in a panel of 36 cell lines (IC70 mean graph) [21]. IC50 represents the amount of drug necessary to 
inhibit the cell growth by 50%. IC70 is the drug concentration that induces a 70% cell growth inhibition. 
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lation to any of the 110 reference compounds was detected 
by COMPARE analysis (ρ<0.6). Auoxo5 (mean IC70=13 
µg/ml), though less potent, was suggested to behave as an 
HDAC inhibitor. 
 Very remarkably, a poor correlation was typically found 
between the antiproliferative effects of the various Auoxos 
and the cytotoxicity profile of CDDP implying that their 
respective modes of action are very different. These findings 
appear to be in good agreement with recent studies suggest-
ing that gold compounds produce their biological effects 
through a mitochondrial mechanism while not causing any 
direct DNA damage. 
 Thus, on the ground of the ONCOTEST protocol and of 
the predictions of COMPARE analysis, two probable bio-
molecular targets have been identified for Auoxo com-
pounds, HDACs and PKc. HDACs form indeed an interest-
ing new family of protein targets for anticancer compounds 
that were never proposed before as candidate targets for gold 
compounds [26]. At variance, it is worth remembering that 
Regala et al. recently suggested that a specific protein kinase 
c might be a target for the gold(I) compound aurothiomalate 
and might be of interest for cancer treatment [27]. 
6. MECHANISTIC STUDIES: REACTIONS WITH 
NUCLEIC ACIDS AND MODEL PROTEINS 
 To gain further insight into the specific reactivity of these 
novel gold(III) compounds with potential biomolecular tar-
gets, the reaction patterns of two representative members of 
the family i.e. Auoxo1 and Auoxo6, with calf thymus DNA 
and with a few model proteins were analyzed in detail by a 
variety of biophysical methods. 
6.1. Reactions with Calf Thymus DNA 
 The interactions of Auoxo1 and Auoxo6 with calf thymus 
DNA were assayed according to an established protocol that 
couples spectroscopic and analytical determinations [14]. 
More in detail, Auoxo1 and Auoxo6 were dissolved in the 
reference phosphate buffer, at 37°C, and an appropriate 
amount of calf thymus DNA was added to both samples in 
such a way to reach r = 0.1 final stoichiometry (where r is 
the gold compound/base pair ratio). Afterward, samples were 
analyzed continuously over 24 h. Highly different spectro-
scopic patterns were observed in the two cases. Indeed, very 
modest perturbations of the characteristic spectral features of 
Auoxo1 were seen after addition of calf thymus DNA (see 
Fig. 7A): the bands characteristic of the gold(III) chromo-
phore were substantially stable over 24 h observation. After 
this period, extensive ultrafiltration of the sample led to 
nearly complete separation of the gold(III) species (which 
crosses the membrane and moves to the lower fraction) from 
calf thymus DNA (which remains in the upper fraction) (Fig. 
7A, inset). Notably, the UV−visible spectrum of the gold(III) 
species, that is recovered in the lower fraction, matches 
rather closely the spectrum of Auoxo1 in the phosphate 
buffer. 
 In contrast, in the case of Auoxo6, upon performing the 
same kind of experiments, a progressive decrease in intensity 
and significant modifications of the bands assigned to the 
gold(III) chromophore were observed over 24 h (Fig. 7B). At 
the end of this period, extensive ultrafiltration failed to sepa-
rate the gold-containing species from DNA. Substantial gold 
binding to DNA was instead demonstrated and then inde-
pendently confirmed by inductively coupled plasma optical 
emission spectroscopy (ICP-OES) measurements (more than 
80% of total gold was found associated with DNA). 
 Such a different behaviour toward calf thymus DNA was 
later confirmed by UV circular dichroism measurements. 
Circular dichroism is indeed a very suitable method to moni-
tor the conformational state of the DNA double helix in solu-
tion and the effects produced by gold drugs [28]. Calf thy-
mus DNA, in its native B-type conformation, is character-
ized by a positive band at 275 nm and a negative one at ca 
242 nm. Remarkably, addition of Auoxo1 to a solution of 
calf thymus DNA, at r = 0.1, produced only modest altera-
tions of the CD spectrum. Some decrease in the intensity of 
the negative band at 242 nm was noticed that could be as-
cribed to a partial loss of DNA helicity (possibly due to oc-
currence of electrostatic interactions between the exposed 
phosphate groups and the positively charged metal complex). 
However, the above CD changes could be reversed nearly 
completely by ultrafiltration against the buffer, implying that 
the Auoxo1/calf thymus DNA interaction is weak and re-
versible in nature. At variance, Auoxo6 resulted to be far 
more effective than Auoxo1 in altering the CD spectra of B-
type DNA. For instance, at r = 0.1, a more pronounced de-
crease of the negative CD band was detected coupled to a 
significant change of the positive band at 275 nm. This latter 
modification could be ascribed to an alteration in the overall 
base stacking of the double helix. Most remarkably, in the 
case of Auoxo6, a weak “induced” CD band also appeared at 
345 nm. All these spectral modifications are diagnostic of 
Table 3. In vitro Anticancer Potency, Tumor Selectivity, and COMPARE Analysis for Selected Auoxos 
Potency Tumor Selectivity 
Compound 
Mean IC50 (µg/ml) Mean IC70 (µg/ml) Selective/Total Selective (%) Rating 
Indicated MoA by COM-
PARE Analysis 
Auoxo1  10.7 24.3 5/36 14 ++ PKC inhibition 
Auoxo4  8.76 21.8 4/36 11 ++ Negative  
Auoxo5  4.45 13.1 2/36 6 + HDAC inhibition 
Auoxo6 0.572 4.44 10/36 28 +++ HDAC inhibition 
MoA mechanism of action, HDAC histone deacetylase, PKC protein kinase C. 
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the formation of a relatively stable Auoxo6/DNA adduct. No 
significant further changes of the CD spectrum were noticed 
following extensive ultrafiltration against the buffer. 
6.2. Reactions with Representative Proteins 
 Subsequently, the reactions of either Auoxo1 or Auoxo6 
with a few model proteins were carried out and analysed 
according to established experimental protocols of our labo-
ratory [2,14,29]. In particular, these two compounds were 
challenged against human serum albumin (hSA), horse heart 
cytochrome c (cyt c), and bovine ubiquitin (Ubq, from red 
blood cells), and the respective reaction batches monitored 
spectrophotometrically over 24 h. 
 The spectral profiles of the reactions of Auoxo1 with 
hSA, cyt c, and Ubq are suggestive of the occurrence of rela-
tively slow reactions between Auoxo1 and the various model 
proteins. Some common trends are easily identified in the 
resulting spectral profiles consisting of the progressive de-
crease of the typical bands of Auoxo1 and of the appearance 
of new bands around 285 nm, characteristic of the free 
ligand. Thus, the obtained spectral patterns may be inter-
preted in terms of the progressive reduction of the gold(III) 
centres by protein side chains. A substantial analogy with 
gold(III) reduction produced by ascorbic acid is evident 
though the kinetics of the reduction process induced by pro-
teins is significantly slower. 
 When Auoxo6 was reacted with the same model proteins, 
somehow similar spectral patterns were found. Again, the 
progressive decay of the characteristic LMCT bands of the 
gold(III) chromophore was observed accompanied by the 























Fig. (7). Time-dependent spectral profiles for Auoxo/DNA adducts at the r = 0.1 stoichiometric ratio. The electronic spectra of 10-5
 
M calf 
thymus DNA were recorded before (a) and after (b) addition of Auoxo1 (A) and Auoxo6 (B) and were followed for 24 h at 37 °C. Results of 
ultrafiltration are shown in the insets. 
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ligand. However, in the case of hSA and cyt c, these redox 
processes were found to be much faster than for Auoxo1.  
At the end of the process most of the added gold was found 
associated with the proteins. The spectral profiles for the 
reaction of Auoxo1 and Auoxo6 with BSA are reported in 
Fig. (8). 
 For both Auoxo1 and Auoxo6, independent ICP-OES 
determinations were carried out on the final solutions, fol-
lowing 24 h of incubation at 37°C and extensive ultrafiltra-
tion against the buffer, working at a metallodrug/protein ra-
tio of 1:1. ICP results pointed out that a very large percent-
age of total gold (>80%) remains in the upper fractions, 
tightly associated with either hSA or cyt c. At variance, in 
the case of ubiquitin, the percentage of gold that is eventu-
ally associated with the protein is only ca 50%. 
 Additional information on the nature of gold/protein ad-
ducts was derived from ESI MS measurements in the case of 
cyt c. ESI MS profiles were collected after reacting cyt c 
with either Auoxo1 or Auoxo6 (Fig. 9), working at 1:1 
Auoxo/cyt c ratios [2]. After 12 h incubation, cyt c was  
extensively ultrafiltered against the ammonium carbonate 
buffer and the ESI MS spectra of the upper fractions  
recorded. 
 In both cases, the final deconvoluted ESI MS spectra 
provided clear evidence of adduct formation. Remarkably, a 
few peaks were detected formally corresponding to the bind-
ing of a number of Au+
 
ions (ranging from 1 to 4) to the pro-
tein. A similar ESI MS behavior was previously reported by 
Sadler et al. for the (Au(PEt3)Cl)/cyclophilin system [30]. It 






















Fig. (8). Time-dependent spectral profiles for 1:1 Auoxo/human SA adducts. Spectra correspond to 10-5 M hSA before (a) and after (b) addi-
tion of Auoxo1 (A) and Auoxo6 (B). The further evolution over 24 h is reported at 37°C. The arrows indicate the changes occurring during 
this period. 
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to gold was found anymore, implying that the reduction 
process causes complete disruption of the starting dinuclear 
compound with cleavage of the oxo bridges, release of the 
bipyridyl ligand, and protein binding of the isolated gold 
ions. 
7. CONCLUDING REMARKS 
 In recent years Auoxos have emerged as an innonative 
class of cytotoxic gold(III) compounds of potential interest 
for the development of new anticancer drugs. Notably, 
Auoxos are dinuclear gold(III) complexes characterised by an 
appreciable solubility and stability in physiological buffers. 
Cytotoxicity assays revealed that Auoxos display very attrac-
tive antiproliferative effects in vitro; however the pattern of 
the measured cytotoxicities is deeply different from that of 
CDDP suggesting the occurrence of a substantially different 
mechanism of action. Significant differences in the biologi-
cal profiles of the various Auoxos were highlighted as well. 
A few targets emerged from COMPARE analysis of the an-
tiproliferative data. In particular important proteins such as 
HDAC and PKC turned out to be likely targets and will be 
further investigated. Interaction studies of Auoxos with calf 
thymus DNA and with a few model proteins were carried out 
as well. Deeply different interaction modes with calf thymus 
DNA were highlighted for Auoxo1 and Auoxo6. At variance, 
biophysical studies of their reactions with a few model pro-
teins strongly suggested that these interactions are dominated 
by redox transformations. Evidence is provided that Auoxos 
are in most cases a source of gold(I) ions which may eventu-
ally bind a variety of protein targets. These findings are in 
accordance with the view that Auoxos behave as prodrugs 
and manifest a high reactivity with several proteins. On the 
ground of the above arguments Auoxos may be considered 
promising cytotoxic agents for further pharmacological test-
ing and development. However, as these gold compounds 
typically manifest a high reactivity with biological molecules 
appropariate strategies might be implemented to control their 
reactivity through specific pharmaceutical formulations (e.g 
nanocapsules or liposomes). Also, “smart” strategies should 
considered for targeting these novel cytotoxic metallodrugs 
selectively to the tumor tissue. 
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